A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
Inclusion Criteria:
Exclusion Criteria:
Tucson, Arizona 85704, United States
La Jolla, California 92037, United States
Atlanta, Georgia 30322, United States
Boston, Massachusetts 02114, United States
Boston, Massachusetts 02114, United States
Boston, Massachusetts 02118, United States
Newark, New Jersey 07112, United States
Houston, Texas 77030, United States
Darlinghurst, New South Wales 2010, Australia
Adelaide, South Australia 5000, Australia
Bedford Park, South Australia 5042, Australia
Parkville, VIC 3050, Australia
Santiago, 8330074, Chile
Cologne, 50924, Germany
Dresden, 01307, Germany
Giessen, 35392, Germany
Budapest, 1096, Hungary
Szeged, 6720, Hungary
Petach Tikvah, 49100, Israel
Naples, 80131, Italy
Palermo, 90127, Italy
Gdansk, 80-952, Poland
Krakow, 31-202, Poland
Lodz, 91-347, Poland
Warsaw, 01-138, Poland
Bucharest, 050159, Romania
Iași, 700115, Romania
Moscow, 105077, Russia
Saint Petersburg, 194156, Russia
Tomsk, 634012, Russia
Seoul, 137-701, South Korea
Khon Kaen, 40002, Thailand
Dnipropetrovsk, 49060, Ukraine
Kyiv, 03680, Ukraine